Liu Biao, An Ran, Yu Jianwei
Department of Obstetrics and Gynecology, Shanxian Central Hospital, Heze, China.
J BUON. 2019 Nov-Dec;24(6):2303-2309.
To investigate the efficacy and safety of bevacizumab (BEV) combined with albumin-bound paclitaxel (ABP) in the treatment of platinum-resistant recurrent ovarian cancer.
Eighty-six patients with platinum-resistant recurrent ovarian cancer admitted to our hospital from March 2014 to March 2016 were enrolled and randomly divided into two groups, namely, BEV + ABP group (n=43, treated with BEV combined with ABP) and ABP group (n=43, treated with ABP alone). Next, the clinical objective response rate (ORR), changes in serum carbohydrate antigen 125 (CA125) level and adverse reactions were compared between two groups. Additionally, the progression-free survival (PFS) and overall survival (OS) were observed and recorded after treatment.
The clinical ORR and disease control rate (DCR) were 86.0% (37/43) and 93.0% (40/43) in BEV + ABP group and 62.8% (27/43) and 79.1% (34/43) in ABP group, respectively. The clinical ORR of patients exhibited a statistically significant difference between two groups (p=0.025), which was overtly higher in BEV + ABP group than that in ABP group, while the DCR had no statistically significant difference between two groups (p=0.117). The serum CA125 level was evidently decreased in both groups after treatment (p<0.05) compared with that before treatment, but it displayed no statistically significant difference between two groups after treatment (p=0.220). The major adverse reactions of patients were myelosuppression, gastrointestinal reaction, alopecia, rash, fatigue and peripheral neurotoxicity. There was no statistically significant difference in the incidence rate of adverse reactions between two groups (p>0.05). All patients were followed up for 6-29 months. The median OS of patients was 16.3 months and 12.6 months in BEV + ABP group and ABP group, respectively, which was clearly longer in BEV + ABP group than that in ABP group (p=0.007). The median PFS in BEV + ABP group was obviously longer than that in ABP group (8.9 months vs. 6.7 months, p=0.028).
In comparison with ABP alone, BEV combined with ABP applied in the treatment of platinum-resistant recurrent ovarian cancer prominently improves the clinical efficacy, PFS and OS, with good tolerance of patients, which is worthy of popularization and application in clinical practice.
探讨贝伐单抗（BEV）联合白蛋白结合型紫杉醇（ABP）治疗铂耐药复发性卵巢癌的疗效及安全性。
选取2014年3月至2016年3月我院收治的86例铂耐药复发性卵巢癌患者，随机分为两组，即BEV + ABP组（n = 43，接受BEV联合ABP治疗）和ABP组（n = 43，仅接受ABP治疗）。接下来，比较两组的临床客观缓解率（ORR）、血清糖类抗原125（CA125）水平变化及不良反应。此外，观察并记录治疗后的无进展生存期（PFS）和总生存期（OS）。
BEV + ABP组的临床ORR和疾病控制率（DCR）分别为86.0%（37/43）和93.0%（40/43），ABP组分别为62.8%（27/43）和79.1%（34/43）。两组患者的临床ORR差异具有统计学意义（p = 0.025），BEV + ABP组明显高于ABP组，而两组的DCR差异无统计学意义（p = 0.117）。与治疗前相比，两组治疗后血清CA125水平均明显降低（p < 0.05），但治疗后两组间差异无统计学意义（p = 0.220）。患者的主要不良反应为骨髓抑制、胃肠道反应、脱发、皮疹、疲劳和周围神经毒性。两组不良反应发生率差异无统计学意义（p > 0.05）。所有患者均随访6 - 29个月。BEV + ABP组和ABP组患者的中位OS分别为16.3个月和12.6个月，BEV + ABP组明显长于ABP组（p = 0.007）。BEV + ABP组的中位PFS明显长于ABP组（8.9个月对6.7个月，p = 0.028）。
与单纯ABP相比，BEV联合ABP用于治疗铂耐药复发性卵巢癌可显著提高临床疗效、PFS和OS，患者耐受性良好，值得临床推广应用。
